PDE4 inhibitors hold promise for treating Alzheimer’s disease (AD) with comorbid depression by targeting the PDE4B and PDE4D subtypes, which regulate mood and memory, respectively [9]. The gene discussed is PDE4A; the disease is early-onset autosomal dominant Alzheimer disease.